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Surgery remains the cornerstone in the early-stage non–small-cell lung cancer (NSCLC) treatment, but a lot of 
efforts have been focused on the use of systemic therapy in 
this setting, on technological advances in thoracic surgery and 
radiotherapy, and on better application of local therapeutic 
approaches to improve the survival rates in these patients.
The aim of this article is to provide a synthetic overview 
of the scientific achievements characterizing this setting dur-
ing the past 40 years (Figure 1).
THORACIC SURGERY FOR EARLY-STAGE NSCLC
For early-stage lung cancer (mainly stages I and II), 
surgery has continued to be a mainstay treatment in the past 
40 years or even longer period. However, there have been 
revision and improvement in many important procedures 
used for the complete resection of lung cancer. The present-
day procedure for the curative resection is composed of the 
removal of lung parenchyma with primary tumor and sam-
pling/dissection of locoregional lymph nodes. In relation 
to these, the determination of proper extent of parenchy-
mal resection for lung cancer and assessment of prognostic 
significance of lymph node dissection have been two major 
issues. In addition to these, the management of earlier lung 
cancers and development of minimally invasive approach 
became the important challenge in the surgical community 
in the past 40 years.
EVOLUTION OF LUNG CANCER SURGERY: 
EXTENT OF PARENCHYMAL RESECTION
The history of lung cancer surgery is that of minimiza-
tion of the extent of parenchymal resection. Lung cancer sur-
gery started as pneumonectomy, a removal of one entire lung 
of either side, in 1930s by the giants in surgical history such 
as Graham, Nissen, and Overholt.1 In late 1950s and 1960s, 
pneumonectomy was gradually being replaced by lobectomy, 
and lobectomy became the standard by the mid-1960s.2 The 
transition from pneumonectomy to lobectomy was based on 
the accumulation of surgeons’ anecdotal but successful experi-
ences. Further progress in lung-sparing resection was afforded 
by the development of “sleeve” resection in 1955.3 Since 
that time, bronchoplastic and angioplastic resections became 
more widely adopted, as evidence accrued that these lung-
sparing operations combined lower perioperative mortality,4 
better functional results,5 improved quality of life,6 and bet-
ter long-term survival in suitable cases7 compared with pneu-
monectomy. Then, the next step toward lesser resection was 
attempted through scientific way of randomized trial by North 
American Lung Cancer Study Group in late 1980s.8 The trial 
compared the prognosis between lobectomy and limited resec-
tion for patients with T1N0 peripheral NSCLC, and the results 
indicated a 75% increase in recurrence rates and 30% increase 
in overall death rate. However, the data on postoperative pul-
monary function were not given because of early funding ter-
mination, and the functional advantage of sublobar resection 
was not clearly demonstrated. It was concluded that lobectomy 
still must be considered the surgical procedure of choice for 
patients with peripheral T1N0 NSCLC. However, especially in 
these days, we are more often encountering earlier and smaller 
lung cancers with predominantly ground-glass appearance on 
high-resolution computed tomography (CT), and their superb 
prognosis has been shown.9 Many case series that demon-
strated the excellent prognosis after sublobar resection equiva-
lent to that after lobectomy are accumulating, although these 
sublobar techniques were not novel.10–12 The need of revision 
of randomized trial between lobectomy and sublobar resec-
tion has been evoked among thoracic surgeons. At present, two 
important randomized trials are actually underway across the 
Pacific Ocean. In the United States, the cancer and leukemia 
group B trial 140503 will randomize small peripheral tumors 
to lobectomy versus limited resection, wedge resection, or 
segmentectomy being allowed in the limited resection arm. In 
Japan, Japan Clinical Oncology Group (JCOG) 0802 study, a 
prospective randomized trial compares the prognoses between 
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lobectomy and segmentectomy in a noninferiority setting.13 
In cancer and leukemia group B trial, primary end point was 
noninferiority of disease-free survival (DFS), and secondary 
end points were noninferiority of overall survival (OS), local 
and systemic recurrence rates, and difference in spirometry at 
6 months. Target accrual is 1297 patients. In Japan Clinical 
Oncology Group trial, the primary end point was noninferi-
ority of OS, and secondary end points were difference in 
spirometry at 6 and 12 months, noninferiority of DFS, local 
recurrence rate, and others. Target accrual is 1100 patients. For 
both these trials, in case the prognosis after segmentectomy is 
not significantly inferior to that of lobectomy and pulmonary 
function after segmentectomy is significantly superior to that 
of lobectomy, segmentectomy is confirmed as a new standard.
Definitive answer to the question whether sublobar resec-
tion can replace lobectomy will be given soon. However, until then 
it is recommended that anatomical segmentectomy be reserved 
for the CT screening–detected pure ground-glass opacity lesions 
or part-solid lesions less than 2 cm located in the peripheral third 
of the lung, after frozen section of N1 and N2 lymph nodes has 
confirmed the T1aN0M0 status. In addition, frozen section or 
cytological evaluation of resection margins is recommended.14
LYMPH NODE DISSECTION FOR LUNG CANCER
Another important aspect of lung cancer surgery is the 
management of the locoregional lymph nodes, because we real-
ize that metastasis to these lymph nodes is strongly prognostic. 
Naruke et al15 published a landmark article in 1978, in which so-
called lymph node map (chart) was introduced for the first time. 
He analyzed the prognosis of patients with metastasis at the 
specific lymph node site and showed a prognostic importance 
to describe the site of lymph nodes. Owing to this nodal chart, 
surgeons became able to speak in the same language of lymph 
nodes. There have been several revisions in lymph node map. In 
United States, Mountain–Dressler American Thoracic Society 
map has been mainly used.16 However, the coexistence of differ-
ent maps caused discrepancy in tumor–node–metastasis (TNM) 
staging worldwide. In 2009, the International Association for 
the Study of Lung Cancer (IASLC) map was promulgated as a 
part of IASLC staging project for the global use.17
An IASLC workshop in 1996 discussed the techniques 
available at that time for intrathoracic nodal evaluation.18 The 
participants, including Dr Naruke, agreed the term “system-
atic nodal dissection” (SND) and defined the minimum stan-
dards for such an assessment. These included the labeling 
of all excised nodes using an internationally accepted nodal 
map, the excision of a minimum of three mediastinal nodal 
stations, one of which should be the subcarinal node, station 
7, and excision of hilar and intrapulmonary nodal stations in 
a centrifugal manner until the extent of resection required 
has been established. Subsequently, a proposal was made that 
the definition of a complete resection should accept SND as 
a requirement for an R0 resection with a minimum of three 
mediastinal and three N1 nodes/stations excised/sampled and 
examined by the pathologist.19 SND was shown to identify 
18% “unexpected N2” disease after preoperative evaluation 
by CT scanning and selective mediastinal exploration.20 The 
development of positron emission tomographic scanning may 
have reduced this incidence by as much as half, but the inac-
curacy of preoperative nodal evaluation remains problem-
atic.21 An alternative approach was suggested by Japanese 
colleagues, Lobe-Specific Nodal Dissection.22 The attraction 
of this technique was the demonstration that the subcarinal 
nodes in station 7 were rarely involved in the case of right 
upper lobe and left upper segment tumors if all other superior 
mediastinal nodal stations were clear of disease on frozen sec-
tion. Although this may save time and a difficult dissection of 
station 7 nodes during video-assisted thoracoscopic surgery 
(vATS) lobectomy, most surgeons find that that removing all 
mediastinal nodes by SND is expedient.
FIGURE 1.  Early-stage non–small-cell lung cancer (NSCLC): overview of the scientific achievements characterizing this setting 
over the last 40 years.
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There has been much debate as to whether such exten-
sive nodal evaluation contributes to cure after complete resec-
tion. One study showed that survival after resection for stage 
I, node-negative, NSCLC improved with the number of lymph 
nodes resected and examined, with a statistically significant cut 
point at six lymph nodes,23 a surprising result given that all such 
nodes were thought to be clear of disease on pathological exam-
ination. However, such an effect could be merely a reflection 
of “stage migration.”24 Studies confirmed that extensive nodal 
excision was more accurate in determining the correct nodal 
category compared with “sampling,”25,26 and one randomized 
prospective trial showed a survival for SND compared with 
sampling.27 To further evaluate the prognostic significance of 
systematic lymph node dissection in comparison with sampling, 
American College of Surgeons Oncology Group conducted a 
large-scale randomized trial with 1100 patients undergoing 
resection for T1-2, N0, or nonhilar N1 NSCLC, randomized 
between mediastinal lymph node dissection (MLND), roughly 
equivalent to systematic nodal dissection and an extensive sys-
tematic sampling (ACOSOG Z0030).28,29 The results indicated 
that in 4% of N2 patients lymph node metastasis was over-
looked in sampling and there was no difference in periopera-
tive indicators such as blood loss and operative time between 
sampling and dissection. Most importantly, lymph node dis-
section did not improve OS or DFS in early-stage lung cancer. 
It was concluded that “MLND provides patients with the most 
accurate staging and the opportunity for adjuvant therapy if 
occult metastatic disease is present. Because current preopera-
tive staging cannot definitively identify patients with mediasti-
nal lymph node involvement and because patients with known 
hilar or mediastinal disease (N2) or with T3 or T4 tumors may 
benefit from MLND because the pretest probability of N2 dis-
ease is higher, we still recommend that all patients with resect-
able NSCLC undergo MLND because the procedure does not 
increase mortality or morbidity.” The discussion regarding the 
prognostic impact of SND has become superfluous since the 
finding that node-positive cases benefit from adjuvant chemo-
therapy.30 In the adjuvant era, it is of paramount importance 
that the surgeon and pathologist collaborate to ensure that the 
determination of the postsurgical/pathological N category is 
conducted using the most rigorous techniques available. In the 
7th edition of TNM for lung cancer, the IASLC lymph node 
map and table of nodal definitions were acknowledged as the 
recognized method for describing regional node involvement 
in lung cancer.22 The definition of an R0 resection has been 
expanded to incorporate the resection and pathological exami-
nation of the minimum number of lymph nodes proposed in the 
definition of SND.31
TREND TOWARD MINIMALLY INVASIVE 
SURGICAL APPROACH
Apart from the extent of parenchymal resection, sur-
geons used various types of chest wall incisions in the past few 
decades. Since the late 1990s, the vATS has been extensively 
used especially for early-stage lung cancers.32 Perioperative 
parameters in patients who underwent lobectomy by either open 
or vATS approach were extensively analyzed, and the consen-
sus has been established that the vATS major lung resection is 
feasible and gives the shorter hospital stay, less morbidity, and 
less cost.33,34 According to the retrospective, multinstitutional 
database analyses of 3961 patients who underwent either open 
lobectomy or vATS lobectomy, vATS procedure was signifi-
cantly superior to open procedure in hospital costs, length of 
stay, and risk of adverse events. Only operative time was longer 
for vATS procedures.32 Similar results were reproduced by a 
propensity-matched analysis of Society of Thoracic Surgeons 
database regarding 5042 open thoracotomy lobectomy and 
1281 vATS lobectomy. Again, vATS lobectomy was associated 
with lower incidence of arrhythmias, reintubation, blood trans-
fusion, shorter stay (4.0 versus 6.0days), and shorter chest tube 
duration. There was no difference in mortality between two 
surgical modalities.35 However, it should be realized that the 
prognostic equivalency between vATS and open procedures 
has not been definitively proved especially in advanced lung 
cancers because the comparison between different modalities 
cannot be completely free from selection bias. Actually, sur-
geons prefer open procedures to vATS procedures in dealing 
with difficult, time-consuming, risky cases. Furthermore, the 
surgical robot is being introduced and applied for the resection 
of lung cancer recently. The robotic procedures are expected 
to facilitate the dissection phase of the resection by provid-
ing a high-resolution binocular view, wrist-like action of the 
instruments, and ease of fine dissection in a confined space. 
Some early reports addressed the low mortality, morbidity, and 
the advantage that it can achieve a good dissection in difficult 
situations.36 However, the disadvantage that there is no tactile 
feedback to surgeons must be mentioned. The feasibility is to 
be evaluated from technical and economical viewpoints.37
STAGING OF LUNG CANCER
Staging of lung cancer is the basis for clinicians to make 
treatment plans and anticipate the outcome. In the past, two 
great leaders played very important roles in revisions of recent 
staging systems: Mountain for 6th edition and Goldstraw for 
7th edition. The IASLC decided to take responsibility for the 
revision of TNM staging system in lung cancer and initiated 
IASLC staging project in 1998.38 Previous revisions of the 
TNM classification for lung cancer had been based on iterative 
analysis of a single institutional database in the United States. 
The cases had been accrued during a period of 40 years and 
were predominantly referred for a surgical opinion. The IASLC 
was able to develop a data set of more than 100,000 cases, 
donated by 46 data centers from more than 20 countries around 
the globe, treated by all modalities of care and accrued dur-
ing a 10-year period. Collection and analysis of these data were 
undertaken by Cancer Research and Biostatistics, a not-for-
profit organization in the United States. Such a huge increase 
in the database available for analysis permitted validation, both 
internal and external, to a degree not possible previously,39 
more closely aligning stage with prognosis than ever before. 
The IASLC proposals for revision38,40–48 were accepted by the 
Union for International Cancer Control and the American Joint 
Committee on Cancer and formed the basis of the 7th edition of 
TNM for Lung Cancer.49,50 The IASLC Staging and Prognostic 
Factors committee is presently working toward the 8th edition 
of TNM due to be published late in 2016. The project will be 
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expanded to include other tumor sites in the thorax: malignant 
pleural mesothelioma, in collaboration with the International 
Mesothelioma Interest Group, and thymic malignancies, in 
association with the International thymic Malignancies Interest 
group. The proposals for the staging classification of lung can-
cer and these other tumor sites will be published in the Journal 
of Thoracic Oncology during the next 12 to 18 months.
Radiotherapy for Early-Stage NSCLC
Surgery remains the cornerstone in the early-stage 
NSCLC treatment, and concerning the role of radiotherapy in 
the adjuvant setting, there is no indication that postoperative 
radiotherapy (PORT) improves outcome in patients with com-
pletely resected N0 or N1 disease, with a meta-analysis in fact 
demonstrating a detrimental effect on survival in these cases. 
For patients in whom unsuspected mediastinal nodal metasta-
ses are discovered during surgery, PORT has not been shown 
to improve OS in prospective randomized studies.51 Ongoing 
trials (LUNGART, NCT00410683) are currently evaluating 
the contribution of PORT delivered through modern tech-
niques in N2 resected patients.
A lot of efforts during the last four decades have been 
focused on technological advances in radiotherapy and on 
a better application of such an alternative local therapeutic 
approach to improve the survival rates in patients considered 
at risk for surgery.52
The apparent reluctance to refer such patients for con-
ventional radiotherapy was partly due to the requirement for 
30 or more once-daily treatments, which is cumbersome for 
frail elderly patients. Moreover, outcomes of conventionally 
fractionated radiotherapy (CFRT) in early-stage NSCLC was 
poor despite treatment to doses ranging from 60 to 66–70 Gy 
because local tumor recurrences were seen in approximately 
40% of patients, with OS at 3 years of approximately 20% 
to 30%.53 Also, hyperfractionation and accelerated hyperfrac-
tionation, used to intensify radiation dose from a biological 
point of view, were ineffective in improving these outcome 
figures, even if not extensively studied in early-stage NSCLC.
when compared with observation, a Surveillance, 
Epidemiology, and End Results registry study demonstrated 
that CFRT alone leads to only modest improvements in out-
comes (median OS = 1.7 years with CFRT versus 1.2 years with 
observation and 5-year OS = 15% versus 14%, respectively).54
In the mid-1990s, the principles of cranial stereotactic 
radiosurgery were transferred to extracranial sites by pioneer-
ing work at the Karolinska Hospital in Sweden.55 This so-called 
stereotactic body radiotherapy (SBRT) approach, also known 
as stereotactic ablative radiotherapy, was further developed 
by centers in Japan,56 Germany,57 and North America.58 In the 
United States, preliminary results from Indiana University led 
to the Radiation Therapy Oncology Group 0236 trial, a phase 
II study that enrolled medically inoperable patients with T1-T2 
(less than 5 cm), peripherally located NSCLC. All patients 
received 60 Gy (20 Gy × 3). Fifty-five patients were enrolled, 
and the results demonstrated a 3-year actuarial LC rate of 98%, 
with OS at 3 years of 56% (median OS of 4 years).59
In subsequent years, encouraging results from both pro-
spective and retrospective studies resulted in rapid adoption 
of SBRT for early-stage NSCLC.60 The rationale of SBRT for 
early-stage NSCLC is that higher radiotherapy doses are more 
effective in locally controlling the tumor (local tumor control 
rates of 90% and higher are achieved, with rates of severe tox-
icity below 10%), which in turn translates into longer OS.
Due to large differences in single fraction and total doses 
between different studies, a comparison of physical doses is 
less meaningful. The current recommended tumor dose for 
SBRT of lung tumors is a minimum of 100 Gy BED, pre-
scribed to the target volume encompassing isodose.61–63 Total 
doses are typically delivered in between one and five frac-
tions. Treatment of tumors in the proximity of critical normal 
organs has led to the used of so-called risk-adapted fraction-
ation schemes that deliver the minimal required dose of 100 
Gy BED in a larger number of lower treatment fractions.64,65
Fractionation appears especially valuable for centrally 
located tumors (tumors located either adjacent to the proxi-
mal bronchial tree or ≤1 cm from the heart or mediastinum) 
because it allows for radiobiological sparing of critical organs.
A higher incidence of complications has been initially 
reported after SBRT for central tumors.66 However, a system-
atic review of the literature indicates that SBRT is a relatively 
safe and effective curative treatment, provided that appropri-
ate fractionation schedules are used for central tumors.67
A favorable therapeutic ratio of high local control and 
simultaneously low toxicity has been maintained even after a 
more widespread adoption of SBRT outside of clinical trials 
and specialized radiotherapy centers.32,68 This finding of repro-
ducible clinical outcome despite relevant variability and time 
trends in SBRT practice suggests that clinical SBRT outcomes 
are fairly robust. Safety profile of SBRT is certainly quite 
good; symptomatic radiation pneumonitis (RP) is uncommon 
after the treatment of peripheral lung tumors measuring 5 cm 
or less, irrespective of the presence of common findings of 
RP/fibrosis on follow-up CT scans.
SBRT is safely practiced also in patients with severe 
pulmonary comorbidities, in patients with and very poor pre-
treatment pulmonary function, and in patients older than 75 
years. A higher incidence of severe RP has been reported only 
in patients with pre-existent idiopathic pulmonary fibrosis.
Milder and risk-adapted fractionation schedules have 
to be used in larger (more than 5 cm) and centrally located 
tumors. More uncommon toxicities reported after SBRT 
include chest wall toxicity such as rib fracture and/or neuro-
pathic pain. At present, SBRT is the guideline-recommended 
nonsurgical treatment of choice for early-stage NSCLC.69
Guidelines for SBRT have been reported by several 
professional groups: very shortly, SBRT is a technique for 
delivering external beam radiotherapy with a high degree of 
accuracy, using high doses of irradiation, which are delivered 
in one or few treatment fractions to an extracranial target.32
SBRT can be adequately performed using either tradi-
tional linear accelerators equipped with suitable image-guid-
ance technology or linear accelerators specifically adapted 
for SBRT and using dedicated delivery systems. The SBRT 
procedure was initially defined by the use of stereotactic 
frame-based patient set-up. However, frame-based stereo-
tactic patient set-up has been replaced by image-guidance 
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(frameless SBRT with image-guidance technologies). with 
nonframe-based patient set-up, external stereotactic coor-
dinates are replaced by visualization of a patient’s anatomy 
using images acquired on-table and subsequently compared 
with pretreatment planning images (image-guided radiother-
apy). Several technologies for image guidance are commer-
cially available, and superiority of one method over the other 
has not been demonstrated. Use of volumetric imaging (cone 
beam CT), as opposed to only implanted fiducials, has the 
advantage of enabling assessment of changes in target shape 
and position, relative to the position of organs at risk.
SBRT: SIMULATION, PLANNING, AND 
TREATMENT DELIVERY
Four-dimensional CT is the recommended technique for 
SBRT simulation, due to its ability to accurately target mov-
ing thoracic tumors and define patient’s specific internal target 
volume .70
For planning, all published prospective trials have used 
three-dimensional conformal treatment planning. Intensity-
modulated radiation therapy (IMRT) and advanced rotational 
techniques such as volumetric modulated arc therapy (vMAT) 
have the potential to increase dose conformity and homogene-
ity and reduce treatment delivery times.71
vMAT is a form of IMRT in which the gantry continu-
ously moves around the patient with a varying speed and rate of 
dose delivery. The maximal dose rate on some of the current lin-
ear accelerators (flattening filter free) using this approach is up 
to four times faster than the standard dose rates most often used.
when using IMRT planning, larger volumes of normal 
pulmonary tissue, including contralateral lung, can be exposed 
to low radiation doses (v
5
); especially when treating larger 
tumors with vMAT-based approach, doses to the contralateral 
lung may predict for the risk of pneumonitis.72
Regarding delivery phase and active motion manage-
ment strategies, continuous irradiation in free breathing is 
performed using the internal target volume concept, the 
mean target position concept, or real-time tumor tracking. 
Noncontinuous irradiation of the tumor in a reproducible 
position is performed using gated beam delivery in predefined 
phases of the breathing cycle.73
FUTURE DIRECTIONS
Currently, the safest dose and fractionation for SBRT 
in centrally located tumors are not known: some ongoing tri-
als will certainly contribute to clarify this issue. The role of 
SBRT in so-called borderline operable patients will also be 
better clarified.
The use of proton radiotherapy is receiving increased 
attention as a modality that is just as effective as photon ther-
apy, but with improved dose distribution in terms of better 
therapeutic ratio; the role of proton SBRT will be promptly 
evaluated, especially for centrally located tumors.
Finally, despite high rates of primary tumor control, the 
rate of distant failure remains consistently high; more work is 
needed to identify biomarkers that may predict those patients 
at risk of developing systemic failures such that these patients 
can be eventually offered adjuvant treatments.
SYSTEMIC TREATMENT FOR  
EARLY-STAGE NSCLC
At the end of the 1970s, it became clear that many 
early-stage NSCLC patients already had occult distant metas-
tases at the time of surgery, which led to predominantly dis-
tant recurrence and death.74 Effective adjuvant therapies thus 
might improve outcome, even if small studies with the avail-
able agents at that time were not effective to demonstrate a 
benefit.75
In the 1980s, several randomized controlled trials (RCTs) 
further studied adjuvant chemotherapy. They were small (less 
than 100 patients per arm), and many used the so-called cyclo-
phosphamide, adriamycin, cisplatin (CAv) regimen. Some 
effects on distant metastasis and DFS could be demonstrated, 
but side effects—emesis in particular—impeded delivery of 
doses that could affect long-term outcome.76,77
In the 1990s, a landmark individual patient–based meta-
analysis on the effect of chemotherapy in NSCLC reported 
the potential benefit of postoperative cisplatin-based chemo-
therapy.78 In the adjuvant setting, the comparison of surgery 
alone versus surgery and chemotherapy gave a hazard ratio 
(HR) for (OS) of 0.87 (13% reduction in the risk of death, 
estimated absolute benefit of 5% in 5-year OS, p = 0.005). 
This meta-analysis was the basis for the statistical design of 
the International Adjuvant Lung Cancer Trial.
The landmark International Adjuvant Lung Cancer Trial 
results were reported in the 2000 decade and were the first 
to indicate the benefit of adjuvant cisplatin-based chemother-
apy in 1867 patients with completely resected stage I to III 
NSCLC.79 This trial, together with several others, both with 
positive80,81 and negative82,83 outcomes, was entered into the 
individual patient–based Lung Adjuvant Cisplatin Evaluation 
meta-analysis.29 In this study of the five largest trials (4584 
patients), the HR of death was 0.89 (95% confidence interval 
(CI) 0.82–0.96; p =.005), corresponding to a 5-year absolute 
benefit of 5.4% with chemotherapy. The benefit varied with 
stage and was documented in stage II, associated with N1 dis-
ease in the 6th edition of TNM used in these studies, and stage 
III, patients with N2 disease in these studies.
In the same decade, several RCTs examining the value 
of neoadjuvant cisplatin-based chemotherapy, started based on 
promising signals in very small-sized trials from the1990s,84,85 
were reported.86–88 These trials were in general of smaller size 
and could not demonstrate a significant improvement in OS. 
A recent meta-analysis on 2385 patients, however, reported a 
very similar HR compared with the adjuvant approach: 0.87 
(95% CI 0.78–0.96, p = 0.007), with an absolute 5-year OS 
improvement of 5%.89
In Japanese patients, several studies looked at adju-
vant use of oral uracil-tegafur for 2 years, based on promis-
ing findings from the1990s. In a RCT with 999 resected stage 
I adenocarcinoma patients, OS was significantly better with 
uracil-tegafur versus standard follow-up: HR 0.71 (95%CI 
0.52–0.98, p = 0.04).90
Postoperative cisplatin-based chemotherapy remains 
limited by toxicity because the most often used regimen of 
cisplatin-vinorelbine is not well tolerated by patients, which 
led to delivery of the planned number of cycles in only 50% 
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to 75% of the patients in the phase 3 studies. Moreover, even 
if clearly significant, effect on OS remains limited. Several 
ways to improve are currently being studied. ways to improve 
are depicted in Figure 2. with surgery alone (left part), around 
40% of the patients will be cured, around 40% will relapse and 
die of lung cancer, and around 20% will die of comorbidity 
(often smoking-related cardiovascular or lung disease). with 
adjuvant chemotherapy (right part), we have brought this to 
45%, 35%, and 20%, respectively.
A first idea is to improve tolerability and thus drug 
delivery of adjuvant chemotherapy. Better anti-emetics such 
as the neurokinin-1 antagonists were an important step. Using 
better tolerated chemotherapy has been examined as well, 
and several trials reported a far lower toxicity and better drug 
delivery with, for example, cisplatin-pemetrexed.91,92
A second way is to use adjuvant therapy only in those 
who are more likely to benefit based on prognostic factors. 
Indeed, nowadays we administer adjuvant treatment to 100 
patients to have an extra cure in 5% of these (number needed 
to treat 20). Examples are the 15-gene signature reported in 
the BR.10 adjuvant trial93 or the 14 gene quantitative poly-
merase chain reaction –based assay.89
A third strategy is enlarging the therapeutic ratio, that 
is, the risk-benefit profile, based on predictive factors. Several 
predictive factors for better activity of chemotherapy have 
been described in retrospective reports, such as expression 
of the excision repair cross-complementation 1 expression 
(ERCC1) for sensitivity to cisplatin,94 thymidilate synthase 
expression for pemetrexed,95 or ribonucleotide reductase 
M1 expression for gemcitabine.96 This principle of so-called 
pharmacogenetic-driven adjuvant chemotherapy is currently 
being explored in several prospective trials. A recent report 
on the French study showed multicenter feasibility of such 
an approach, but further development was stopped because 
of unreliable ERCC1 readouts, due to different antibodies 
reacting with different isoforms.59 Moreover, recent phase 
3 confirmatory pharmacogenetic studies in the setting of 
advanced NSCLC were disappointingly negative.97,98 So, 
albeit attractive, the principle of biomarker-driven adjuvant 
chemotherapy clearly needs further technical refinement 
before patient benefits can be expected.
The past decade has also seen the marked increase in the 
development of novel therapeutic strategies targeting signaling 
pathways, such as epidermal growth factor receptor (EGFR), 
angiogenesis, and, more recently, immunotherapy in stage Iv 
NSCLC. The potential contribution of these strategies in the 
adjuvant setting is still a matter of debate. More than 1000 
patients were included in a phase III trial (NCIC BR.19) origi-
nally designed to evaluate the efficacy of gefitinib versus placebo 
in unselected patients with resected stage IB to IIIA NSCLC dis-
ease; unfortunately this study was prematurely stopped because 
of the negative results of other gefitinib studies.99–101 No overall 
survival benefit was detected with adjuvant gefitinib in the 503 
patients included, and results were also inconclusive among 
EGFR mutant patients. Another phase III study (RADIANT) is 
comparing erlotinib with placebo in patients with resected stage 
IB to IIIA NSCLC after being treated with adjuvant chemo-
therapy (ClinicalTrials.gov, NCT00373425). Eligible patients 
include those with EGFR mutation, gene amplification, or pro-
tein expression.102 Erlotinib did not prolong disease free sur-
vival in these NSCLC completely resected population.
The role of bevacizumab (added to cisplatin-based che-
motherapy) in the same disease setting is currently under eval-
uation in Eastern Cooperative Oncology Group 1505 study, a 
randomized phase III trial in completely resected stage IB to 
IIIA NSCLC.
MAGE-A3 vaccine is a cancer immunotherapy that is 
being developed specifically in the adjuvant setting in patients 
with resected NSCLC, where MAGE-A3 antigen is expressed 
in 33% of the tumor samples. On the basis of a phase II study 
in which patients who received MAGE-A3 vaccine had a non-
significant improvement in DFS and OS compared with pla-
cebo, a large phase III trial was designed and 2270 patients 
were enrolled. Unfortunately, at the beginning of 2014 it was 
announced that the trial did not meet its first and second co-
primary end points. There was no significant improvement 
in DFS compared with placebo in either the overall MAGE-
A3–positive population (first co-primary end point) or in 
those MAGE-A3–positive patients who did not receive che-
motherapy (second co-primary end point). Also a third end 
point based on a previously identified gene signature predict-
ing efficacy of MAGE-A3 vaccine was not reached.
CONCLUSIONS
Surgery remains the standard treatment for early-stage 
NSCLC. In the past 40 years, a lot of improvements have been 
made in this setting with the introduction of modern surgi-
cal techniques and radiotherapeutic approaches, alternative 
treatments to sublobar resection—in patients with borderline 
medical criteria for surgery—based on SBRT, and the com-
plementary role of systemic treatments has been definitively 
established.
Nevertheless, many issues are still a matter of debate, 
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context (Figure 1). Here are only some of the topics that are 
under investigation in early stages: the extent of parenchymal 
resection, the role of robotic surgery, a better definition of the 
role of SBRT, the role of IMRT as adjuvant treatment, and 
an update of the PORT meta-analyses, which will include 
last-generation radiation techniques. In the area of systemic 
treatment, the impact of pharmacogenomic factors, definition 
of prognostic and predictive factors, and the role of targeted 
drugs and immunotherapy are only some of the main themes 
worth of investigation.
The IASLC is the only international association group-
ing together all the specialists involved in the early disease 
approach and, consequently, the only scientific association 
potentially able to promote and support initiatives devoted to 
implement knowledge in this field.
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